XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Xeris Biopharma Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.95+0.64 (+6.21%)
Close on Oct 19, 2026
- Market cap
- $1.89B
- P/E (TTM)
- –
- Dividend yield
- –
Xeris Biopharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Xeris Biopharma | Industry median |
|---|---|---|
| Market Cap | $2.00B | $197.05M |
| Enterprise Value | $2.13B | $106.56M |
| PS Ratio | 5.95 | 3.93 |
| P/OCF Ratio | 35.27 | 13.78 |
Enterprise value
| Measure | Xeris Biopharma | Industry median |
|---|---|---|
| EV / Sales | 6.34 | 2.69 |
| EV / EBITDA | 56.09 | 14.86 |
| EV / EBIT | 58.13 | 19.00 |
Income (trailing twelve months)
| Measure | Xeris Biopharma | Industry median |
|---|---|---|
| Revenue | $335.41M | $57.94M |
| Gross Profit | $290.39M | $90.47M |
| Operating Income | $36.59M | -$21.44M |
| Net Income | -$17.17M | -$22.46M |
| EBITDA | $37.93M | -$16.91M |
| EPS (Diluted) | -$0.12 | -$0.83 |
Margins
| Measure | Xeris Biopharma | Industry median |
|---|---|---|
| Gross Margin | 86.6% | 52.3% |
| Operating Margin | 10.9% | -44.5% |
| Profit Margin | -5.12% | -39.2% |
| EBITDA Margin | 11.3% | -31.3% |
Returns
| Measure | Xeris Biopharma | Industry median |
|---|---|---|
| Return on Assets (ROA) | -4.60% | -41.0% |
| Return on Invested Capital (ROIC) | 22.1% | -32.0% |
| Return on Capital Employed (ROCE) | 16.5% | -37.8% |
Growth
| Measure | Xeris Biopharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 36.3% | 6.01% |
| Revenue Growth (3Y CAGR) | 38.3% | 2.25% |
| Revenue Growth (5Y CAGR) | 70.2% | 6.42% |
Balance sheet
| Measure | Xeris Biopharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $121.75M | $62.42M |
| Total Debt | $252.59M | $120.13M |
| Net Cash (Debt) | -$130.84M | $15.68M |
| Net Cash Per Share | -$0.72 | $0.65 |
| Equity (Book Value) | -$9.73M | $48.79M |
| Book Value Per Share | -$0.05 | $1.36 |
| Tangible Book Value | -$115.25M | $23.06M |
| Working Capital | $85.19M | $75.77M |
Financial position
| Measure | Xeris Biopharma | Industry median |
|---|---|---|
| Current Ratio | 1.45 | 3.30 |
| Quick Ratio | 0.95 | 2.39 |
| Debt / EBITDA | 6.66 | 3.35 |
| Net Debt / EBITDA | 3.45 | 2.22 |
| Interest Coverage | 1.30 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Xeris Biopharma | Industry median |
|---|---|---|
| Operating Cash Flow | $56.61M | -$12.35M |
Efficiency
| Measure | Xeris Biopharma | Industry median |
|---|---|---|
| Asset Turnover | 0.90 | 0.38 |
| Inventory Turnover | 0.61 | 2.67 |
| Revenue Per Employee | $771.07K | $398.96K |
| Profits Per Employee | -$39.46K | -$732.08K |
| Employee Count | 435 | 73 |
Dividends and yields
| Measure | Xeris Biopharma | Industry median |
|---|---|---|
| Earnings Yield | -0.86% | -21.2% |
Shares
| Measure | Xeris Biopharma | Industry median |
|---|---|---|
| Shares Outstanding | 182,320,000 | 59,128,900 |
| Shares Change (YoY) | 21.8% | 11.1% |
| Shares Change (QoQ) | 0.60% | 0.54% |
| Float | 172,830,000 | 48,744,500 |
| Shares Held by Insiders | 5.21% | 11.8% |
| Shares Held by Institutions | 59.4% | 59.4% |
Taxes
| Measure | Xeris Biopharma | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Xeris Biopharma | Industry median |
|---|---|---|
| Altman Z-Score | 1.82 | 0.10 |
| Piotroski F-Score | 8 | 4 |
| Beneish M-Score | -2.59 | -2.62 |
Calculated by StockData from Xeris Biopharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.